Duato Joaquin
CEO and Chairman of the Board at JNJ
- Sold, on record
- $101M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Aug 13, 2026
- Form 144 notices
- 2
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- JNJJOHNSON & JOHNSONCEO and Chairman of the Board
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale JNJUnusualMar 3, 2017 2017
Sold 50,000 shares at $123.62 ($6.2M)
Duato Joaquin, Exec VP, WW Chair, Pharma
Sold 42.2% of holdings ($14.7M position)68,536 shares leftFirst sale on recordFiling
- 2 Form 4 sale JNJUnusualNov 7, 2018 +614 days
Sold 40,000 shares at $144.36 ($5.8M)
Duato Joaquin, Vice Chair, Exec Committee
Sold 30% of holdings ($19.3M position)93,555 shares leftFiling
- 3 Form 144 notice JNJNoticeAug 22, 2025 +2480 days
Filed to sell 125,824 shares ($22.7M)
Duato Joaquin, Officer, Director
No 10b5-1 planFirst sale on recordFiling
- 4 Form 4 sale JNJUnusualAug 22, 2025 same day
Sold 125,824 shares at $179.21 ($22.5M)
Duato Joaquin, CEO and Chairman of the Board
No 10b5-1 planSold 31.3% of holdings ($72M position)275,967 shares leftFirst sale on recordFollows a Form 144Filing
- 5 Form 144 notice JNJNoticeJan 26, 2026 +157 days
Filed to sell 100,000 shares ($22M)
Duato Joaquin, CEO, Chariman
No 10b5-1 planFiling
- 6 Form 4 sale JNJUnusualJan 26, 2026 same day
Sold 100,000 shares at $221.23 ($22.1M)
Duato Joaquin, CEO and Chairman of the Board
No 10b5-1 planSold 76.4% of holdings ($28.9M position)30,852 shares leftFollows a Form 144Filing
- 7 Form 4 sale JNJNo planAug 5, 2026 +191 days
Sold 48,480 shares at $258.15 ($12.5M)
Duato Joaquin, CEO and Chairman of the Board
No 10b5-1 planSold 14.9% of holdings ($83.8M position)275,967 shares leftFiling
- 8 Form 4 sale JNJUnusualAug 13, 2026 +8 days
Sold 123,291 shares at $261.17 ($32.2M)
Duato Joaquin, CEO and Chairman of the Board
No 10b5-1 planSold 30.9% of holdings ($104M position)275,967 shares left1.2x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (8)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 14, 2026 | JNJ | CEO and Chairman of the Board | Form 4 sale | 123,291 | $32.2M | 30.9% | Unusual | SEC |
| Aug 5, 2026 | Aug 7, 2026 | JNJ | CEO and Chairman of the Board | Form 4 sale | 48,480 | $12.5M | 14.9% | No plan | SEC |
| Jan 26, 2026 | Jan 28, 2026 | JNJ | CEO and Chairman of the Board | Form 4 sale | 100,000 | $22.1M | 76.4% | Unusual | SEC |
| Jan 26, 2026 | Jan 26, 2026 | JNJ | CEO, Chariman | Form 144 notice | 100,000 | $22M | Notice | SEC | |
| Aug 22, 2025 | Aug 25, 2025 | JNJ | CEO and Chairman of the Board | Form 4 sale | 125,824 | $22.5M | 31.3% | Unusual | SEC |
| Aug 22, 2025 | Aug 22, 2025 | JNJ | Officer, Director | Form 144 notice | 125,824 | $22.7M | Notice | SEC | |
| Nov 7, 2018 | Nov 9, 2018 | JNJ | Vice Chair, Exec Committee | Form 4 sale | 40,000 | $5.8M | 30.0% | Unusual | SEC |
| Mar 3, 2017 | Mar 7, 2017 | JNJ | Exec VP, WW Chair, Pharma | Form 4 sale | 50,000 | $6.2M | 42.2% | Unusual | SEC |